The effectiveness of nirsevimab in reducing the burden of disease due to respiratory syncytial virus (RSV) infection over time in the Madrid region (Spain): a prospective population-based cohort study

Immunization with nirsevimab is an effective measure for reducing the burden of care related to RSV at all levels of care albeit it decreases throughout follow-up. At 150 days it remained high for preventing hospital admissions. Other articles already published have also demonstrated high effectiveness although with preliminary results, short follow-up periods and wide confidence intervals. None have detected a decrease in effectiveness over time. These results can be quite useful in individual infant prevention and in the design of immunization campaigns.

Authors

Institutions

Publication Details

Journal
Frontiers in Public Health
Published
2024-08-16
DOI
https://doi.org/10.3389/fpubh.2024.1441786
Citations
56
Primary Topic
Respiratory viral infections research
Type
article
Field-Weighted Citation Impact
21.65

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The effectiveness of nirsevimab in reducing the burden of disease due to respiratory syncytial virus (RSV) infection over time in the Madrid region (Spain): a prospective population-based cohort study

Marta Molina Olivas, Cristina Calvo, María D. Esteban‐Vasallo, María Ángeles Gutiérrez Rodríguez et al.
56 citations
Frontiers in Public Health
Respiratory viral infections research
21.65
article

The effectiveness of nirsevimab in reducing the burden of disease due to respiratory syncytial virus (RSV) infection over time in the Madrid region (Spain): a prospective population-based cohort study

Marta Molina Olivas, Cristina Calvo, María D. Esteban‐Vasallo, María Ángeles Gutiérrez Rodríguez, José Francisco Barbas del Buey, Marcos Alonso-García, Jesús Íñigo Martínez, Manuel Sánchez Luna, Amaya Sánchez‐Gómez, María Dolores Lasheras Carbajo, Susana Jiménez Bueno, María Araceli Arce Arnáez, María Alejandra López Zambrano
article en
56 citations

Abstract

Immunization with nirsevimab is an effective measure for reducing the burden of care related to RSV at all levels of care albeit it decreases throughout follow-up. At 150 days it remained high for preventing hospital admissions. Other articles already published have also demonstrated high effectiveness although with preliminary results, short follow-up periods and wide confidence intervals. None have detected a decrease in effectiveness over time. These results can be quite useful in individual infant prevention and in the design of immunization campaigns.

Frontiers in Public HealthVol. 12
Universidad Complutense de Madrid (ES), Hospital Universitario La Paz (ES), Hospital General Universitario Gregorio Marañón (ES), Hospital La Paz Institute for Health Research (ES), Comunidad de Madrid (ES), Bioef - Fundación Vasca de Innovación e Investigación Sanitarias (ES), Universidad Autónoma de Madrid (ES)
Comunidad de Madrid
Good health and well-being
Openalex Percentile: Top 0%
Respiratory viral infections research
21.65
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.